Proceedings on Cancer-Immuno-Oncology
Proceedings on Cancer-Immuno-Oncology
Infinite Science Publishing
Verified email at infinite-science.de - Homepage
TitleCited byYear
Activation of MDA5 improves anti-tumor therapy and reduces suppressive capacity of myeloid-derived suppressor cells
P Metzger, SV Kirchleitner, M Kluge, LM König, S Endres, CC Friedel, ...
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810042, 2018
12018
Combining anti-VEGF-A and anti-PD-L1 therapy prolongs overall survival in small cell lung carcinomas
L Meder, P Schuldt, M Thelen, A Schmitt, F Dietlein, S Klein, S Borchmann, ...
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810057, 2018
2018
Specific targeting of oncogenic mutations using CRISPR-technology to destroy activated oncogenes and enhance immune response
F Oppel, M Schürmann, H Sudhoff
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810046, 2018
2018
Effects of EGFR-MEK-ERK pathway on PD-L1 expression in head and neck squamous cell carcinoma
C Rong, B Feng, M Muller, D Holzinger, C Flechtenmacher, J Thierauf, ...
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810047, 2018
2018
Killing melanoma cells with ROS provides immuno-protection against tumor growth in vivo
E Freund, R Clemen, RK Gandhirajan, S Bekeschus
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810055, 2018
2018
CD8+ T cell response to HPV16 E7 predicts survival outcome in oropharyngeal cancer
H Sudhoff, L Masterson, P Jani, JC Sterling, P Goon
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810050, 2018
2018
Which adjuvants for tumor-antigen vaccination induce powerful non-sialylated IgG antibodies?
Y Bartsch, M Ehlers
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810053, 2018
2018
Pre-and intratherapeutic cellular monitoring for dose adjustment of chemotherapy in aggressive lymphoma
J Schröder, S Rödiger, M Ruhe, PM Deckert
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810056, 2018
2018
Regulatory T cells in endogenous mouse lymphoma are antigen-specific nTregs and provide a target for immune checkpoint-inhibiting therapies
V Bauer, F Ahmetlic, T Riedel, N Trautwein, T Sparwasser, S Stevanovic, ...
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810045, 2018
2018
Current status of radiotherapy/radiochemotherapy and immunotherapy combinations–a German survey
L Käsmann, C Eze, O Roengvoraphoj, C Belka, F Manapov
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810051, 2018
2018
Activation of immune response in refractory patients to standard treatment (TRANSLATE)
A Abbona, D Sangiolo, M Merlano, O Garrone, M Anna, M Monteverde, ...
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810052, 2018
2018
Effect of both PD-1/PD-L1 and ERK inhibitor on triple negative breast cancer cell lines and the non-triple negative cell line MCF-7
E Kabore, F Köster, S Polack, A Rody, K Bräutigam
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810044, 2018
2018
The emerging role of extracellular vesicles in clinical research inflammation, cancer progression, metastasis
F Ender, M Klee, M Kramer, A Merseburger, R Pries, G Riemekasten, ...
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810048, 2018
2018
Effect of both PD-1/PD-L1 and ERK inhibitor on Cisplatin-sensitive (HEY) and Cisplatin-resistant (HEY-Cis) ovarian cancer cell lines
P Vogt, F Köster, S Polack, A Rody, K Bräutigam
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810043, 2018
2018
Biparatopic heavy chain antibodies (bi-hcAbs): fusion of two distinct CD38-specific nanobodies into a human IgG1 bi-hcAb results in potent CDC vs. myeloma cells
K Schütze, J Hambach, K Petry, W Fumey, B Albrecht, L Schriewer, ...
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810041, 2018
2018
Neo-adjuvant checkpoint inhibition–the pathway towards personalized immunotherapy
C Blank
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810023, 2018
2018
Modulating the tumor microenvironment
D Jäger
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810027, 2018
2018
Role of glycolysis for intestinal inflammation and carcinogenesis
J Hamm, K Klischies, N Sommer, P Rosenstiel, F Sommer
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810037, 2018
2018
CAR NK cells for cancer retargeting
R Esser, U Koehl, W Glienke, M Morgan, A Kaiser, H Abken, M Heuser, ...
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810009, 2018
2018
Immune modulation by extracellular vesicles released from mesenchymal cells
M Seifert
Proceedings on Cancer-Immuno-Oncology 1 (1), DOI: 10.18416/CIO.2018.1810006, 2018
2018
The system can't perform the operation now. Try again later.
Articles 1–20